Knowledge of adeno-associated variant’s infection pathway is based on only a few serotypes. The prevailing understanding is that serotypes bind to different, or have differential affinities to an array of primary cell surface glycoprotein receptors and secondary receptors.
Pharmaceutical research energy is now being focused on studies to elucidate if the lower performance of therapies for some racial minorities or gender are based on these serotype differences.By studying these less understood serotypes, it may be possible to uncover a mechanism that not only works for more patients, but might just work better per se.
